Predictions
MacroGenics Inc.
Start price
Target price
Perf. (%)
€14.88
05.12.21
05.12.21
-
05.12.22
05.12.22
0.47%
12.12.21
12.12.21
Risky Investment
Novavax Inc.
Start price
Target price
Perf. (%)
€147.98
05.12.21
05.12.21
-
05.12.22
05.12.22
-23.17%
07.01.22
07.01.22
Could be worthwhile Investment >10% per year
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.42
03.12.21
03.12.21
-
03.12.22
03.12.22
7.50%
11.12.21
11.12.21
Risky Investment
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€4.62
03.12.21
03.12.21
-
03.12.22
03.12.22
0.84%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Krystal Biotech
Start price
Target price
Perf. (%)
€66.00
01.12.21
01.12.21
€50.00
31.12.23
31.12.23
16.67%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Ardelyx Inc.
Start price
Target price
Perf. (%)
€0.99
30.11.21
30.11.21
€1.00
30.11.22
30.11.22
36.36%
11.12.21
11.12.21
Could be very worthwhile Investment >20% year
Good culture
Innovative
Few uniques
Athersys Inc.
Start price
Target price
Perf. (%)
€23.38
30.11.21
30.11.21
€25.00
30.11.22
30.11.22
-71.89%
07.07.22
07.07.22
Could be worthwhile Investment >10% per year
Innovative
Few uniques
Krystal Biotech
Start price
Target price
Perf. (%)
€77.00
29.11.21
29.11.21
-
29.11.22
29.11.22
-19.48%
10.12.21
10.12.21
Probably not worthwhile Investment
Acorda Therapeutics Cdt
Start price
Target price
Perf. (%)
€2.64
28.11.21
28.11.21
-
28.11.22
28.11.22
-77.46%
29.11.22
29.11.22
Risky Investment
Inovio Pharma
Start price
Target price
Perf. (%)
€6.45
27.11.21
27.11.21
€3.30
27.11.22
27.11.22
-52.69%
12.04.22
12.04.22
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Axsome Therapeutics Inc
Start price
Target price
Perf. (%)
€32.27
16.11.21
16.11.21
€25.00
16.11.22
16.11.22
59.84%
16.11.22
16.11.22
Could be very worthwhile Investment >20% year
Kezar Life Sciences
Start price
Target price
Perf. (%)
€10.20
16.11.21
16.11.21
€11.00
31.12.24
31.12.24
0.98%
28.06.22
28.06.22
Could be very worthwhile Investment >20% year
Curis Inc.
Start price
Target price
Perf. (%)
€5.06
14.11.21
14.11.21
-
14.11.22
14.11.22
-83.10%
15.11.22
15.11.22
Probably not worthwhile Investment
Apellis Pharmaceuticals
Start price
Target price
Perf. (%)
€37.80
13.11.21
13.11.21
€50.00
31.12.23
31.12.23
11.71%
29.06.22
29.06.22
Could be very worthwhile Investment >20% year
Novavax Inc.
Start price
Target price
Perf. (%)
€145.98
11.11.21
11.11.21
€75.00
11.11.22
11.11.22
-63.74%
11.04.22
11.04.22
Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
Avenue Therapeutics Inc.
Start price
Target price
Perf. (%)
€16.95
11.11.21
11.11.21
€30.00
11.11.22
11.11.22
-21.68%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
EyePoint Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€13.70
09.11.21
09.11.21
€20.00
09.11.22
09.11.22
-62.04%
09.11.22
09.11.22
Could be very worthwhile Investment >20% year
Enanta Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€85.00
05.11.21
05.11.21
€100.00
31.12.23
31.12.23
-63.76%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Codexis Inc.
Start price
Target price
Perf. (%)
€34.80
05.11.21
05.11.21
€50.00
31.12.23
31.12.23
-79.99%
07.09.22
07.09.22
Could be very worthwhile Investment >20% year
Revance Therapeutics Inc.
Start price
Target price
Perf. (%)
€12.40
01.11.21
01.11.21
€15.00
01.11.22
01.11.22
79.03%
02.11.22
02.11.22
Could be worthwhile Investment >10% per year
Krystal Biotech
Start price
Target price
Perf. (%)
€42.60
30.10.21
30.10.21
€37.00
30.11.22
30.11.22
54.93%
01.12.21
01.12.21
Could be very worthwhile Investment >20% year
Otonomy Inc.
Start price
Target price
Perf. (%)
€1.67
25.10.21
25.10.21
€3.00
31.12.23
31.12.23
21.68%
28.06.22
28.06.22
Could be very worthwhile Investment >20% year
Novavax Inc.
Start price
Target price
Perf. (%)
€117.42
20.10.21
20.10.21
€105.00
20.10.22
20.10.22
24.32%
11.11.21
11.11.21
Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float